Novotech, a global full-service clinical Contract Research Organization (CRO), has released an in-depth report, "Bladder Cancer – Global Clinical Trial Landscape 2024," providing insights for stakeholders in oncology and clinical research. The report examines clinical trial trends, emerging therapeutic strategies, and regional variations in patient outcomes.
Bladder cancer remains a significant global health challenge, with over 614,000 new cases and 220,600 deaths recorded in 2022. The report offers a detailed examination of the evolving landscape in bladder cancer research.
Key Findings on Bladder Cancer Research
The Novotech report includes several key findings:
- Bladder Cancer Statistics: Europe and Asia account for the majority of global cases.
- Clinical Trial Landscape: Over 1,500 bladder cancer clinical trials have been initiated since 2019, with North America, Asia-Pacific, and Europe leading in trial volume.
- Advancements in Treatment: Innovative therapies, including immunotherapy, targeted treatments, and combination therapies, are opening new avenues in bladder cancer care.
- Future Projections: Bladder cancer cases are projected to exceed 1.2 million annually by 2050, underscoring the urgent need for advanced treatment options and accessible healthcare solutions.
Insights for Biotech and Oncology Professionals
The report offers valuable information for biotech professionals, oncologists, researchers, and scientists. By examining trial density, recruitment efficiencies, and regional disparities in treatment outcomes, the report provides actionable insights for those aiming to enhance the efficiency and effectiveness of bladder cancer trials.
Novotech's Role in Oncology Advancement
Founded in 1997, Novotech is a global full-service CRO focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. The company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, and regulatory expertise. Novotech has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies.
